title: Frequency of apnea, bradycardia, and desaturations following first diphtheria-tetanus-pertussis-inactivated polio-Haemophilus influenzae type B immunization in hospitalized preterm infants.
abstract: BACKGROUND
  Adverse cardiorespiratory events including apnea, bradycardia, and desaturations have been described following administration of the first diphtheria-tetanus-pertussis-inactivated polio-Haemophilus influenzae type B (DTP-IPV-Hib) immunization to preterm infants. The effect of the recent substitution of acellular pertussis vaccine for whole cell pertussis vaccine on the frequency of these events requires further study.
  
  
  METHODS
  Infants with gestational age of < or = 32 weeks who received their first DTP-IPV-Hib immunization prior to discharge from two Edmonton Neonatal Intensive Care Units January 1, 1996 to November 30, 2000 were eligible for the study. Each immunized infant was matched by gestational age to one control infant. The number of episodes of apnea, bradycardia, and/or desaturations (ABD) and the treatment required for these episodes in the 72 hours prior to and 72 hours post-immunization (for the immunized cohort) or at the same post-natal age (for controls) was recorded.
  
  
  RESULTS
  Thirty-four infants who received DTP-IPV-Hib with whole cell pertussis vaccine, 90 infants who received DTP-IPV-Hib with acellular pertussis vaccine, and 124 control infants were entered in the study. Fifty-six immunized infants (45.1%) and 36 control infants (29.0%) had a resurgence of or increased ABD in the 72 hours post-immunization in the immunized infants and at the same post-natal age in the controls with an adjusted odds ratio for immunized infants of 2.41 (95% CI 1.29,4.51) as compared to control infants. The incidence of an increase in adverse cardiorespiratory events post-immunization was the same in infants receiving whole cell or acellular pertussis vaccine (44.1% versus 45.6%). Eighteen immunized infants (14.5%) and 51 control infants (41.1%) had a reduction in ABD in the 72 hours post- immunization or at the equivalent postnatal age in controls for an odds ratio of 0.175 (95%CI 0.08, 0.39). The need for therapy of ABD in the immunized infants was not statistically different from the control infants. Lower weight at the time of immunization was a risk factor for a resurgence of or increased ABD post-immunization. Birth weight, gestational age, postnatal age or sex were not risk factors.
  
  
  CONCLUSIONS
  There is an increase in adverse cardiorespiratory events following the first dose of DTP-IPV-Hib in preterm infants. Lower current weight was identified as a risk factor, with the risk being equivalent for whole cell versus acellular pertussis vaccine. Although most of these events are of limited clinical significance, cardiorespiratory monitoring of infants who are sufficiently preterm that they are receiving their first immunization prior to hospital discharge should be considered for 72 hours post-immunization.
authors.affiliation: Stollery Children's Hospital and Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada. jr3@ualberta.ca.
authors.forename: Jackie
authors.initials: J
authors.lastname: Lee
authors.forename: Joan L
authors.initials: JL
authors.lastname: Robinson
authors.forename: Donald W
authors.initials: DW
authors.lastname: Spady
mesh_terms: D000416:Alberta / Q000453:epidemiology; D001049:Apnea / Q000453:epidemiology / Q000209:etiology*; D001724:Birth Weight; D001835:Body Weight; D001919:Bradycardia / Q000453:epidemiology / Q000209:etiology*; D002673:Child, Hospitalized; D015331:Cohort Studies; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D005260:Female; D005865:Gestational Age; D018073:Haemophilus Vaccines; D006801:Humans; D000860:Hypoxia / Q000453:epidemiology / Q000209:etiology*; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000453:epidemiology / Q000209:etiology*; D008297:Male; D011054:Poliovirus Vaccine, Inactivated; D012307:Risk Factors; D014611:Vaccination / Q000009:adverse effects*; D022282:Vaccines, Acellular / Q000009:adverse effects; D017778:Vaccines, Combined / Q000009:adverse effects*
chemical_list: C513012:DTP-IPV-Hib vaccine; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D018073:Haemophilus Vaccines; D011054:Poliovirus Vaccine, Inactivated; D022282:Vaccines, Acellular; D017778:Vaccines, Combined